Zhou Rong sold $75K of AMPH

Amphastar (AMPH) reported Q3 2026 revenue of $207.6M, up 8% YoY, driven by BAQSIMI and Primatene MIST sales. Gross margin fell to 48% due to pricing pressures and IMS facility remediation costs. EPS rose to $1.14. The company increased its share buyback program by $50M and expects high single-digit Q4 growth. IMS backlog stands at $12.5M due to operational constraints. Insulin aspart launch is targeted for 2027, pending FDA approval.

Amphastar Pharmaceuticals reported Q3 2026 revenue of $207.6M, up 8% YoY, with adjusted EPS of $1.14. CFO Bill Peters addressed pricing headwinds, IMS remediation costs, and growth drivers like Baximi and Primatene Mist. The company expects continued lidocaine demand but constrained capacity. Insulin biosimilar launches are planned for 2027, with margin normalization dependent on higher volumes. Q4 sales are expected to grow in the high single digits.

Amphastar Pharmaceuticals reported Q3 gross margin decline to 48% from 51% YoY, citing lower pricing for BAQSIMI and increased manufacturing costs. The company expects higher remediation expenses in coming quarters. Amphastar aims to reduce a $12.5M backlog and sees continued lidocaine demand. It remains on track for potential 2027 launches of insulin aspart biosimilar and AMP-018, with other pipeline updates. Operating cash flow was $43.3M, and the board authorized $50M for share repurchases.

Amphastar Pharmaceuticals (AMPH) reported Q3 2026 revenue of $207.6M, up 8.2% YoY and 5.9% above estimates. Adjusted EPS of $1.14 beat estimates by 32.8%. Operating margin was 24.5%, in line with the prior year. The company cited strong sales of key products and pipeline advancements. Shares rose 7.2% post-results.

Amphastar Pharmaceuticals reported Q3 2026 revenue of $207.61M, up 8.2% YoY, and net income of $37.76M, up 117.7% YoY. Growth in BAQSIMI, Primatene MIST, and lidocaine sales offset declines in epinephrine and glucagon. New ipratropium bromide sales contributed $6.6M. Lower expenses also boosted income.

Amphastar reported Q3 2026 revenue of $207.6M, up 8% YoY, with GAAP net income of $37.8M. Adjusted EPS was $1.14. Key products like BAQSIMI and Primatene MIST saw sales growth, while Lidocaine and Ipratropium bromide performed strongly. Teriparatide and API sales also contributed to growth. Manufacturing issues impacted some product sales and expenses.